DIACOMIT is the only FDA-approved antiseizure medication specifically for seizures associated with Dravet syndrome in children as young as 6 months. It is indicated for patients weighing 15 pounds or more and taking clobazam.
DIACOMIT® (stiripentol) is an effective, FDA-approved medication that was developed specifically to treat seizures associated with Dravet syndrome. It is indicated for patients 6 months and older (weighing 15 lb or more) taking clobazam. There are no clinical data to support the use of DIACOMIT as monotherapy in Dravet syndrome.1
DIACOMIT may help patients achieve profound seizure reduction so families can celebrate everyday wins.1
Join our email list to receive the latest information and resources regarding DIACOMIT. We’ll keep you informed without overwhelming your inbox.